Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 7/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 7/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 7/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 7/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 7/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 7/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24608829 | 0.98 | GPR84 (0.38) | GPR84PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23219755 | 0.98 | GPR84 (0.38) | GPR84PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23489973 | 0.87 | PSEN1 (0.34) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22758634 | 0.83 | NR1I2 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18948474 | 0.83 | NR1I2 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5541964 | 0.83 | HCAR2 (0.31) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22926088 | 0.79 | ALDH1A1 (0.39) | GPR84PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL24659233 | 0.76 | GPR84 (0.35) | GPR84PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL18602282 | 0.71 | HCAR2 (0.32) | HCAR2 | |
| SCHEMBL19003676 | 0.71 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20210355121-A1 | FUSED TRICYCLIC KRAS INHIBITORS | INCYTE CORPORATION | 2021-11-18 | — | — | US | disclosed |
| EP-3587406-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-2968316-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2019-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | GPR84 119/4885PSEN1 1264/4885PSEN2 1685/4885 |
| US-20210355121-A1 | FUSED TRICYCLIC KRAS INHIBITORS | KRAS, NRAS, HRAS | GPR84 3663/4885PSEN1 2979/4885PSEN2 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.